Klinická farmakologie a farmacie – 2/2021

KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm 2021; 35(2): 60–68 / www.klinickafarmakologie.cz 68 HLAVNÍ TÉMA Kardiovaskulární nežádoucí účinky protinádorové léčby 42. https://www.uptodate.com/contents/cardiotoxicity-of- -trastuzumab-and-other-her2-targeted-agents/abstract/4 Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfun- ction: time to recognize a newentity. J ClinOncol 2005; 23: 2900. 43. https: //www.acc.org/latest-in-cardiology/articles/2018/ 05/04/08/41/type-i-and-type-ii-cardiomyopathy-classifica- tions-are-complete-nonsense-pro (citováno dne 1.3.2021) 44. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008; 26: 5204–5212. 45. https: //www.uptodate.com/contents/toxicity-of-mole­ cularly-targeted-antiangiogenic-agents-cardiovascular- effects (citováno dne 1.3.2021). 46. https: //www.nccn.org/professionals/physician_gls/pdf/ immunotherapy.pdf (citováno dne 1.3.2021). 47. Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune Checkpoint Inhibitor Myocarditis: Pathophysiolo- gical Characteristics, Diagnosis, and Treatment. J Am Heart Assoc. 2020; 9(2): e013757. doi: 10.1161/JAHA.119.013757. Epub 2020 Jan 21. PMID: 31960755; PMCID: PMC7033840. 48. Garanta S, Neilan M. Immune Checkpoint Inhibitor-Asso- ciat ed Myocar ditis, The Oncologist, 2018; 23: 879–886. http: //dx.doi.org/10.1634/theoncologist.2018–0130, (citováno dne 1.3.2021) 2018; 23: 518–523. 49. https: //www.accessdata.fda.gov/drugsatfda_docs/ label/2012/020212s013lbl.pdf, citováno dne 1/3/2021. 50. Bosch X, RoviraM, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM et al. Enalapril and carvedilol for preventing chemo- therapy-induced left ventricular systolic dysfunction in patients withmalignant hemopathies: theOVERCOME trial (Prevention of left Ventricular dysfunctionwith Enalapril and Carvedilol in pati- ents submitted to intensive Chemotherapy for the treatment of Malignant Hemopathies) J AmColl Cardiol. 2013; 61: 2355–2362. 51. Gulati G, Heck SL, Ree AH et al. Prevention of cardiac dy- sfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double- -blind clinical trial of candesartan and metoprolol. Eur He- art J 2016; 37: 1671–1680. 52. Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, Jr, et al. Carvedilol for Prevention of Chemotherapy-Related Car- diotoxicity: The CECCY Trial.J Am Coll Cardiol. 2018; 71(20): 2281–2290. 10.1016/j.jacc.2018.02.049. 53. Cardinale D, Ciceri F, Latini R et al. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The Interna- tional CardioOncology Society-one trial. Eur J Cancer. 2018; 94: 126–37. 10.1016/j.ejca.2018.02. 54. Boekhout AH, Gietema JA, Milojkovic Kerklaan B, et al. Angiotensin II-Receptor Inhibition With Candesartan to Pre- vent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2016; 2(8): 1030–1037. 10.1001/jamaoncol.2016.1726 (PubMed). 55. Pituskin E, Mackey JR, Koshman S et al. Multidisciplina- ry Approach to Novel Therapies in Cardio-Oncology Rese- arch (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol 2017; 35: 870–877. 56. Guglin M, Munster P, Fink A et al. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer re- ceiving trastuzumab: A rationale and design of a randomi- zed clinical trial. Am Heart J. 2017; 188: 87–92. 57. Akpek M, Ozdogru I, Sahin O et al. Protective effects of spironolactone against anthracycline-induced cardiomyo- pathy. Eur J Heart Fail. 2015; 17(1): 81–89. 10.1002/ejhf.196. 58. Acar Z, Kale A, Turgut M et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011; 58(9): 988–989. 10.1016/j.jacc.2011.05. 59. Naumann D, Rusius V, Margiotta C, Nevill A, Carmichael A, Rea D et al. Factors predicting trastuzumab-related car- diotoxicity in a real-world population of women with HER2+ breast cancer. Anticancer Res. 2013; 33(4): 1717–1720. 60. Thavendiranathan P, Poulin F, Lim KD et al. Use of myo- cardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after ca- ncer chemotherapy: a systematic review, J Am Coll Cardiol, 2014; 63: 2751–2768. 61. Curigliano G, Lenihan D, Fradley M et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations, Annals of Oncology, 2020; 31(2): 171–190. 62. Woods T, Vidarsson B, Mosher D, Stein JH. Transient effu- sive-constrictive pericarditis due to chemotherapy. Clin Car- diol. 1999; 22: 316–318.